The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines. In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We have found the activation of caspase-3 and poly-(ADPribose) polymerase in telomestatin-treated U937 cells (PD20) and dominant-negative DN-hTERT-expressing U937 cells (PD25). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells (PD20) and dominantnegative DN-hTERT-expressing U937 cells (PD25); however, activation of JNK and ASK1 was not detected in these cells. To examine the effect of p38 MAP kinase inhibition on growth properties and apoptosis in telomerase-inhibited cells, we cultured DN-hTERT-expressing U937 cells with or without SB203580. Dominant-negative-hTERT-expressing U937 cells stopped proliferation on PD25; however, a significant increase in growth rate was observed in the presence of SB203580. Treatment of SB203580 also reduced the induction of apoptosis in DNhTERT-expressing U937 cells (PD25). These results suggest that p38 MAP kinase has a critical role for the induction of apoptosis in telomerase-inhibited leukemia cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatintreated animals exhibited marked apoptosis. None of the mice treated with telomestatin displayed any signs of toxicity. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.
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Introduction
Telomerase is a cellular RNA-dependent DNA polymerase that serves to maintain the tandem arrays of telomeric TTAGGG repeats at eukaryotic chromosome ends (Blackburn and Greider, 1995) . Telomeres are essential DNA-protein structures that cap and protect the end of eukaryotic chromosome from illegitimate recombination, degradation and detection as DNA damage. The reactivation of telomerase activity in most cancer cells supports the concept that telomerase is a relevant target in oncology, and telomerase inhibitors have been proposed as new potential anticancer agents (Bearss et al., 2000; White et al., 2001; Ohyashiki et al., 2002) . One effective strategy for designing telomerase inhibitors is to target telomerase indirectly via the telomeric substrate aiming to block the interaction between the enzyme and the telomere (Bearss et al., 2000) . At the extreme 3 0 -termini of telomeres, there are regions of single-stranded DNA formed owing to the limitations of DNA polymerization known as the endreplication problem (Watson et al., 1972; Olovnikov et al., 1973) . Each of these regions have a guanine (G)-rich, single-stranded structure assembled around a core stack of guanines arranged in almost-planar, hydrogenbonded tetrads. Ionic conditions that favor quadruplex formation have been shown to inhibit telomerase, and small molecules that stabilize or promote formation of quadruplexes also have shown inhibitory activity (Zahler et al., 1991; Sun et al., 1997; Wheelhouse et al., 1998; Izbicka et al., 1999) . Therefore, stabilization of G-quadruplexes can be considered an original strategy to achieve antitumor activity.
Several classes of agents are potent inhibitors of telomerase and display strong affinities for G-quadruplex structures (Mergeny et al., 1998) . Small molecules that selectively stabilize the telomeric G-quadruplex induce telomere shortening and replicative senescence (Gowan, et al., 2001 (Gowan, et al., , 2002 Shin-ya et al., 2001; Riou et al., 2002; Tauchi et al., 2003) . Among those, telomestatin appears very promising owing to its high selectivity towards quadruplexes as compared to other nucleic acid conformations (Shin-ya et al., 2001; Tauchi et al., 2003) . Telomestatin induces apoptosis in different tumor cell types and displays a selectivity towards cancer cells as compared to normal progenitor cells (Kim et al., 2002 (Kim et al., , 2003 Gomez et al., 2003; Tauchi et al., 2003; Shammas et al., 2004) . Telomere shortening is also observed in cells treated with telomestatin, but arises earlier than expected for a single mechanism involving telomerase inhibition Gomez et al., 2004) . In the present study, we investigated the mechanisms of apoptosis induced by telomerase inhibition in acute leukemia. We found the activation of caspase-3 and poly-(ADP-ribose) polymerase (PARP) in telomestatin-treated U937 cells (PD20). Activation of p38 mitogen-activated protein (MAP) kinase and MKK3/6 was also found in telomestatin-treated U937 cells. Further, we evaluated the effect of telomestatin on the growth of U937 cells in xenograft mouse model. Systemic intraperitoneal administration of telomestatin in U937 xenografts decreased tumor telomerase levels and reduced tumor volumes. Tumor tissue from telomestatin-treated animals exhibited marked apoptosis. Taken together, these results lay the foundations for a program of drug development to achieve the dual aims of efficacy and selectivity in vivo.
Results
Effects of telomestatin and the expression of DN-hTERT on telomerase activity and telomere length in U937 cells We have previously shown that inhibition of telomerase by DN-hTERT reproducibly results in telomere shortening and induction of DNA damage-associated apoptosis in human leukemia cells Nakajima et al., 2003) In order to study the mechanisms of apoptosis induced by telomerase inhibition in leukemia cells, first we show the effects of telomestatin and the expression of DN-hTERT on telomerase activity in human acute myelomonocytic leukemia cell line, U937. U937 cells were cultured with telomestatin for 48 h. DN-hTERT-expressing U937 cells (PD25) were generated as described previously . Telomerase activity from each cell line was analysed by telomere repeat amplification protocol (TRAP) assay (Figure 1a) . Treatment of 10 mM of telomestatin and the expression of DN-hTERT showed the significant reduction of telomerase activity in U937 cells (Figure 1a) . We next defined the telomere shortening by the presence of 2 mM of telomestatin and the expression of DN-hTERT in U937 cells (Figure 1b) . Periodically, total DNA samples were prepared from indicated cell lines, and digested with frequently cutting restriction enzymes and the telomere length was examined by Southern blotting (Figure 1b ). In the presence of 2 mM of telomestatin, the terminal restriction fragment (TRF) length of U937 cells shortened progressively from 9.5 to 3.8 kb at population doubling (PD) 20. The TRF length of DN-hTERTexpressing U937 cells showed 3.4 kb at PD25.
Effects of telomestatin on normal diploid human fibroblasts and alternative lengthening of telomerespositive cells We evaluated the effects of telomestatin on normal diploid human fibroblasts (BJ cells and IMR-90 cells) and alternative lengthening of telomere (ALT)-positive GM847 cells. Short-time (3 days) exposure to telomestatin at concentration up to 5 mM did not affect the viability of normal human fibroblasts BJ or IMR-90; however, 5 mM of telomestatin reduced the viability of GM847 cells (data not shown). We used 2 mM of telomestatin as the treatment condition in long-term cultivation experiments for GM847 cells. Treatment of BJ or IMR-90 cells with 2 or 5 mM of telomestatin did not significantly change the proliferation rate or viability to that of control cells (Figure 2a and b). Treatment of 2 mM of telomestatin also did not change the proliferation of GM847 cells (Figure 2c ). These results suggest that telomestatin has less effect on normal diploid human fibroblasts and ALT-positive cells. 
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The telomere shortening associated with DNA-damageinduced apoptosis is associated with caspase-3 activation One of the molecular events associated with DNA damage-induced apoptosis is the cleavage of caspase-3 proenzyme into a caspase-3 active form. Therefore, we examined the activation of caspase-3 and PARP in telomesatin-treated U937 cells and DN-hTERT-expressing U937 cells. U937 cells were cultured with 2 mM of telomestatin for indicated periods (PD0, PD5, PD10 and PD20). DN-hTERT-expressing U937 cells (PD25) were also used as positive controls of telomerase inhibition. Cell lysates from telomestatin-treated cells (PD0, PD5, PD10 and PD20) or DN-hTERT-expressing cells (PD25) were immunoblotted with anticleaved caspase-3 antibody (Ab) or anticleaved PARP Ab (Figure 3a and b). Caspase-3 and PARP were activated in cell lysates from telomestatin-treated U937 cells (PD20) and DNhTERT-expressing U937 cells (PD25), but not in lysates from early passaged telomestatin-treated U937 cells (PD0, PD5 and PD10) (Figure 3a and b) . These results indicate the involvement of caspase-3 activation in the telomerase inhibition associated apoptosis.
p38 MAP kinase is activated in telomestatin-treated U937 cells and DN-hTERT-expressing U937 cells As p38 MAP kinase plays causative roles in senescent normal fibroblast cells following telomere shortening (Iwasa et al., 2003) , we examined the phosphorylation of p38 MAP kinase, JNK and ASK1, in telomestatintreated U937 cells and dominant-negative (DN)-hTERT-expressing U937 cells. We found a four-to fivefold increase in the amount of phosphorylated p38 Telomerase inhibition and targeted therapy T Tauchi et al MAP kinase in telomestatin-treated U937 cells (PD20) and DN-hTERT-expressing U937 cells (PD25) (Figure 4a ). Phosphorylation of JNK and ASK1 in U937 cells was not altered by telomestatin and DNhTERT (data not shown). MKK3/6 is regulated as the responsible kinase for p38 MAP kinase activation after various stimulations; therefore, we examined the phosphorylation of MKK3/6. Telomestatin and DN-hTERT also enhanced the phosphorylation of MKK3/6 in U937 cells (Figure 4b ). Effects of SB203580 on cell proliferation and inhibition of apoptosis in telomestatin-treated U937 cells and DN-hTERT-expressing U937 cells. To study the roles of p38 MAP kinase in cell proliferation and apoptosis, a p38 MAP kinase inhibitor, SB203580, was applied for the following studies. The growth kinetics of telomestatin-treated U937 cells and DN-hTERT-expressing U937 cells initially did not differ from those of control cells (Figure 5a ). However, after 30 days, telomestatintreated U937 cells and DN-hTERT-expressing U937 cells showed an almost complete inhibition of proliferation (Figure 5a ). In the presence of SB203580, a significant increase in growth rate was observed in DN-hTERT-expressing U937 cells (Figure 5a ). To determine whether p38 MAK kinase inactivation affect the apoptosis in telomestatin-treated U937 cells and DN-hTERT-expressing U937 cells, we employed flow cytometry analysis with APO2.7 antibody (Figure 5b ). Cultivation with SB203580 for 72 h markedly decreased the population of APO2.7-positive cells from 54.573.5 to 26.771.7% in telomestatin-treated U937 cells (PD20) (Figure 5b ). Cultivation with SB203580 also decreased the population of APO2.7-positive cells from 45.776.6 to 8.571.4% in DN-hTERT-expressing cells (PD25) (Figure 5b ). These results indicate that p38 MAP kinase has a critical role for the growth kinetics and the induction of apoptosis in telomerase-inhibited leukemia cells.
Systemic telomestatin treatment decreased tumor telomerase activity and inhibited the growth of U937 xenografts To further study the activity of telomestatin on tumor growth in vivo, we used xenografts of U937 cells in nude mice. When the tumors were established to a size of Telomerase inhibition and targeted therapy T Tauchi et al 100 mm   3 , mice were treated with intraperitoneal injections of phosphate-buffer saline (PBS) (n ¼ 5) or telomestatin (15 mg/kg, n ¼ 5) two times a week for 4 weeks (Figure 6a ). We found that telomestatin treatment significantly reduced tumor growth in U937 xenograft (Figure 6a ). U937 xenograft treated with PBS for 21 days had a mean tumor volume of 13957270 mm 3 compared with telomestatin treated with a mean tumor volume of 291714 mm 3 (Figure 6a ). Mice treated with systemic telomestatin treatment exhibited no adverse effects (body weight loss, clinical signs or survival). Telomerase activity from tumor cells was also examined by a TRAP assay after 48 h treatment (Figure 6b ). Systemic administrations of 3 mg/kg or 9 mg/kg or 15 mg/kg of telomestatin decreased tumor telomerase activity by 60.2, 74 and 92.5% compared to control, respectively (Figure 6b ). To evaluate whether administration of telomestatin results in induction of apoptosis in U937 cells in vivo, we examined the histology of tumors after telomestatin treatment (15 mg/kg, two times a week; day 21). Excised tumor or bone marrow samples were sectioned and stained with hemotoxylin and eosin (H &E) or TdT-mediated dUTP nick-end labeling (TUNEL) (Figure 6c ). Tumors of control mice were composed of densely packed U937 cells with no feature of apoptosis (Figure 6c ). Tumors from telomestatin-treated mice revealed an increased fraction of dead cells, identified by their amorphous shape and condensed nuclei (Figure 6c ). Dead tumor cells and areas of degenerative tissue were observed, appearing as loosely arranged cells with the occurrence of vacuolated structures. Feature of apoptosis were observed in the tumor sections stained with TUNEL ( Figure 6c ). Administration of telomestatin also reduced U937 cells in bone marrow and recovered the normal hematopoiesis (Figure 6c ).
Discussion
Inhibition of telomerase activity by pharmacological or genetic interventions has been demonstrated to result in continuous telomere erosion, which ultimately induces replicative senescence or apoptosis. Telomerase inhibition does not immediately affect tumor cell growth, but will lead to a delay effect that is dependent on sufficient telomere decapping upon proliferation . We have previously demonstrated that telomestatin induced telomere shortening in human leukemia cells earlier than expected for a simple mechanism involving telomerase inhibition . Recent observation demonstrated that treatment of telomesatin resulted in a marked decrease in the 3 0 -overhang signal, which correlated with the onset of the growth arrest (Gomez et al., 2004) .
In the present study, we examined the mechanisms of apotosis induced by telomestatin in acute leukemia. We demonstrated that caspase-3 activation, a key executioner of apoptosis is associated with telomestatin and DN-hTERT-induced apoptosis (Figure 3a) . We have also observed the PARP activation in telomestatin- treated U937 cells and DN-hTERT-expressing U937 cells (Figure 3b ). Poly-(ADP-ribose) polymerase is activated during the DNA damage response, and it is involved in the base-excision repair, being cleaved by caspases into two fragments of 115 and 85 kDa, during apoptosis (Ame et al., 1999; Schreiber et al., 2002) . Poly-(ADP-ribose) polymerase is the only characterized nuclear protein whose catalytic activity is stimulated by DNA strand break (Ame et al., 1999; Schreiber et al., 2002) . Our results support the idea of relationship between telomerase inhibition-induced DNA damage and PARP activation.
The p38 MAP kinase pathway mediates responses to environmental stresses, including DNA-damaging agents such as UV-and g-irradiation (Nebreda et al., 2000; Wang et al., 2000) . A recent study reported that the activation of p38 MAP kinase contributes to the onset of cellular senescence induced by telomere shortening in human fibroblasts (Iwasa et al., 2003) . We have shown that telomestatin-treatment (PD20) and DNhTERT-expression (PD25) enhanced the phosphorylation of p38 MAP kinase and MKK3/6 in U937 cells (Figure 4a and b) . We have also shown that inhibition of p38 MAP kinase by SB203580 restored the proliferation in DN-hTERT-expressing U937 cells after PD25 (Figure 5a ). The inhibition of p38 MAP kinase by SB203580 decreased the population of apoptosis in telomestatin-treated U937 cells and DN-hTERT-expressing U937 cells (Figure 5b ). These results indicate that p38 MAP kinase has a critical role for the growth kinetics and the induction of apoptosis in telomeraseinhibited leukemia cells. Several lines of evidence suggest the association between telomestatin-induced telomere dysfunction and p38 MAP kinase activation. First of all, the activation of MKK3/6 and p38 MAP kinase occurred after PD20 in telomestatin-treated U937 cells (Figure 4a and b) . This suggests that the treatment of 2 mM of telomestatin does not directly activate MKK3/6 and p38 MAP kinase. DN-hTERT-expression also activates MKK3/6 and p38 MAP kinase at PD25 (Figure 4a and b) . In addition, the telomere loss induced by telomestatin led to telomere dysfunction . Replicative senescence is induced not by the complete loss of telomeric repeats, but by the loss of telomeric function to protect chromosomes from end-toend fusions (Karlseder et al., 2002) . Therefore, accumulation of genetic dysfunctions caused by telomestatin is responsible for p38 MAP kinase activation.
We have previously reported that telomestatin also had less effect on burst-forming unit-erythroid and colony-forming unit-grammulocyte/macrophase colony formation of normal bone marrow CD34-positive cells . There are some difficulties inherent in using in vitro normal hematopoietic cell systems to evaluate the long-term cytotoxicities. In order to evaluate the long-term effects of telomestatin on normal cells, we treated normal diploid human fibroblasts with telomestatin over 40 days (Figure 2a and b) . We observed that telomestatin had less effect on normal BJ or IMR-90 fibroblasts, suggesting a high anticancer specificity (Figure 2a and b) . We also observed that telomestatin had minimum effects on ALT-positive GM847 cells (Figure 2c) . In contrast to telomestatin, TMPyP4, a compound that preferentially facilitates the formation of intermolecular G-quadruplex structures, suppresses the proliferation of ALT-positive cells. Kim et al. (2003) reported that this difference is caused by the selectivity of compounds for either the intramolecular (telomestatin) or the intermolecular (TMPyP4) Gquadruplex structures.
We evaluated the in vivo activity of telomestatin in U937 xenografts ( Figure 5 ). We demonstrated that treatment with telomestatin (15 mg/kg/day, intraperitoneally) was capable of achieving significant downregulation of telomerase activity in U937 cells in vivo, and that this was associated with antitumor activity (Figure 6a and b). Histological examination of these tumors by TUNEL staining revealed significant induction of apoptosis, suggesting that the changes in tumor volume may reflect a large population of apoptotic cells (Figure 6c ). Intraperitoneal treatment of telomestatin (up to 15 mg/kg) exhibited no significant adverse effects compared with PBS-treated mice. Specifically, no differences in weight loss, or clinical symptoms were observed between telomestatin-and control-treated mice. Although we are unable to resolve the precise mechanism regarding with telomere shortening more than expected, it is clearly a feature that has significant implications for therapeutic applications and warrants further investigation.
In summary, we demonstrate that the telomestatin can cause effective reductions in telomerase activity that lead to induction of antitumor activity. These results, which should not be extrapolated to other types of tumors, highlight the complexity of the cell death process and the myriad of intracellular changes that may be required to achieve it. This, in turn, may shed some additional light on the cellular requirements for the development of effective and specific therapeutic strategies. Generation of stable clones expressing DN-hTERT mutants pBABE-DN-hTERT was a gift from Dr Robert Weinberg (Massachusetts Institute of Technology). U937 cells were transfected with the expression vector pBABE-puro-DNhTERT by electroporation. Beginning 48 h after electroporation, cells were selected with 2 mg/ml of puromycin and cloned by limiting dilution. PD0 was defined as the time at which cultures reached confluence in 10-cm culture dishes.
Materials and methods

Antibodies and reagents
Telomerase assay and measurement of TRF Telomerase activity was examined by a TRAP assay using a TRAP EzE telomerase detection kit (Oncor, Gaithersburg, MD, USA). The polymerase chain reaction (PCR) products were subjected to 12% acrylamide denaturing electrophoresis in an automated laser fluorescence DNA sequencer II (Pharmacia LKB Biotechnology, AB, Canada) and analysed by the Fragment Manager program (Pharmacia LKB Biotechnology, AB, Canada). Activity in the extract-based PCR TRAP assay was detected as a periodic 6 bp peak of telomerase products and, in each sample, relative telomerase activity was calculated semiquantitatively in comparison with a 36-bp internal standard. To measure TRF, genomic DNA was digested with the restriction enzymes HinfI and RsaI, fractionated on 0.7% agarose gels and transferred onto nylon membranes. Hybridization was performed by using the Telo TTAGGG telomere length assay kit (Roche Molecular Biochemicals, Mannheim, Germany).
Apoptosis assay
The incidence of apoptosis was determined by flow cytometric analysis with the fluorescein isothiocynate-conjugated APO2.7 monoclonal antibody (clone 2.7), which was raised against the 38 kDa mitochondrial membrane protein (7A6 antigen) and is expressed by cells undergoing apoptosis (Nakajima et al., 2001) .
Immunoblotting and immunoprecipitation
Immunoblotting and immunoprecipitation were performed as described previously (Tauchi et al., 1994) .
Antitumor effect in vivo
We studied the antitumor effect of telomestatin in mice bearing U937 cells. Tumors were observed 4 weeks after cells were injected into the back of 6-week-old female nude mice. In this study, we started to treat these animals 4 weeks after tumor inoculation, once transplantability was confirmed (tumor weight was 100 mm 3 ). These mice were treated with telomestatin (15 mg/kg, intraperitoneally two times a week) or PBS for 28 days. Mice were observed daily, and body weight as well as signs of stress (e.g., lethargy, ruffled coat or ataxia) were used to detect possible toxicities. Average tumor weight per mouse was calculated and was used to analyse the group mean tumor weight7s.e. (n ¼ 5 mice).
Tumor and tissue processing
Tumors were collected at selected times and fixed in paraformaldehyde. Paraffin-embedded tissues were sectioned and processed for gross histopathology by H.&E. staining and TUNEL staining.
